Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive us adults with attenuated salmonella typhi oral vaccine CVD 908-htrA

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1452-1458

  Muhsen, Khitam ^a   Pasetti, Marcela F ^a   Reymann, Mardi K ^a   Graham, David Y ^b,c   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Helicobacter pylori; humoral immunity; immunogenicity; oral vaccines; Salmonella Typhi; serum pepsinogens

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BIOLOGICAL MARKER; CAGA PROTEIN; CVD 908 HTRA LIVE ORAL TYPHOID VACCINE; HEPATITIS A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; O ANTIGEN; PEPSINOGEN I; PEPSINOGEN II; PLACEBO; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LOW DRUG DOSE; MALE; NORMAL HUMAN; OBESITY; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; SEX DIFFERENCE; UNITED STATES; VACCINATION; YOUNG ADULT;

HELICOBACTER PYLORI; HUMORAL IMMUNITY; IMMUNOGENICITY; ORAL VACCINES; SALMONELLA TYPHI; SERUM PEPSINOGENS;

ADOLESCENT; ADULT; COHORT STUDIES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MALE; MULTIVARIATE ANALYSIS; PLACEBOS; SALMONELLA TYPHI; SALMONELLA VACCINES; UNITED STATES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84898654571     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit625     Document Type: Article

References (44)

1. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83:49-59
2. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 2:1165-9
3. Levine MM, Sztein MB, Pasetti MF. The immunological basis for immunization series: Module 20: Salmonella enterica serovar Typhi (typhoid) vaccines. Geneva:World Health Organization, 2011
4. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1:1049-52
5. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17 (suppl 2):S22-7
6. Tacket CO, Sztein MB, Losonsky GA, et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997; 65:452-6
7. Tacket CO, Sztein MB, Wasserman SS, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68:1196-201
8. Kirkpatrick BD, McKenzie R, O'Neill JP, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006; 24:116-23
9. Lyon CE, Sadigh KS, Carmolli MP, et al. In a randomized, doubleblinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7×10(10) colonyforming units. Vaccine 2010; 28:3602-8
10. Wahid R, Pasetti MF, Maciel M Jr., et al. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhispecific IgA and IgG B memory cells in humans. Clin Immunol 2011; 138:187-200
11. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: Lessons from a live cholera vaccine. BMC Biol 2010; 8: 129
12. Jiang V, Jiang B, Tate J, Parashar UD, Patel MM. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin 2010; 6:532-42
13. Wahdan MH, Serie C, Germanier R, et al. A controlled field trial of liver oral typhoid vaccine Ty21a. Bull World Health Organ 1980; 58: 469-74
14. Lagos R, Fasano A, Wasserman SS, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999; 180:1709-12
15. Cooper PJ, Chico ME, Losonsky G, et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 2000; 182:1199-206
16. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175-86
17. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997; 113:S43-9
18. Feldman M, Cryer B, Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol 1998; 274: G1011-7
19. Bhan MK, Bahl R, Sazawal S, et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J Infect Dis 2002; 186:1857-60
20. Vollaard AM, Verspaget HW, Ali S, et al. Helicobacter pylori infection and typhoid fever in Jakarta, Indonesia. Epidemiol Infect 2006; 134:163-70
21. Blaser MJ, Rafuse EM, Wells JG, Pollard RA, Feldman RA. An outbreak of salmonellosis involving multiple vehicles. Am J Epidemiol 1981; 114:663-70
22. Taylor DN, Bied JM, Munro JS, Feldman RA. Salmonella Dublin infections in the United States, 1979-1980. J Infect Dis 1982; 146:322-7
23. Bowen A, Newman A, Estivariz C, et al. Role of acid-suppressing medications during a sustained outbreak of Salmonella enteritidis infection in a long-Term care facility. Infect Control Hosp Epidemiol 2007; 28:1202-5
24. Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 2006; 4:306-14
25. He CY, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: A neglected but useful biomarker to differentiate between diseased and normal stomachs. J Gastroenterol Hepatol 2011; 26:1039-46
26. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003; 88:1239-47
27. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007; 8:15-22
28. Bell BP, Kruszon-Moran D, Shapiro CN, Lambert SB, McQuillan GM, Margolis HS. Hepatitis A virus infection in the United States: Serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 2005; 23:5798-806
29. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 2004; 190: 565-70
30. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 1973; 78:271-6
31. Matsuda F, Chowdhury MI, Saha A, et al. Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, doubleblind, placebo-controlled trial in Bangladeshi children under 5 years of age. Vaccine 2011; 29:1855-8
32. Sobala GM, Crabtree JE, Dixon MF, et al. Acute Helicobacter pylori infection: Clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991; 32:1415-8
33. Malaty HM, El-Kasabany A, Graham DY, et al. Age at acquisition of Helicobacter pylori infection: A follow-up study from infancy to adulthood. Lancet 2002; 359:931-5
34. Biasco G, Paganelli GM, Vaira D, et al. Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients. J Clin Pathol 1993; 46:826-8
35. Ganga-Zandzou PS, Michaud L, Vincent P, et al. Natural outcome of Helicobacter pylori infection in asymptomatic children: A two-year follow-up study. Pediatrics 1999; 104:216-21
36. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-Term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31:546-50
37. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-Term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345:1525-8
38. Sipponen P, Kekki M, Seppala K, Siurala M. The relationships between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther 1996; 10 (Suppl 1):103-18
39. Derakhshan MH, El-Omar E, Oien K, et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J Clin Pathol 2006; 59: 1293-9
40. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and-positive Japanese subjects. J Gastroenterol 2005; 40:938-44
41. Perez-Perez GI, Salomaa A, Kosunen TU, et al. Evidence that cagA(+) Helicobacter pylori strains are disappearing more rapidly than cagA(-) strains. Gut 2002; 50:295-8
42. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859-65
43. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011; 239:125-48
44. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007; 45 (Suppl 1):S15-9.